Publication:
Tyrosine kinase inhibitors in the treatment of metastatic renal cell cancer patients with early cytokine intolerance: TURCOS, a Turkish national, prospective observational study

Simple item page
dc.contributor.authorDANE, FAYSAL
dc.contributor.authorsBenekli, Mustafa; Gumus, Mahmut; Ozkan, Metin; Dane, Faysal; Elkiran, Emin T.; Cicin, Irfan; Sevinc, Alper; Aliustaoglu, Mehmet; Isikdogan, Abdurrahman; Meydan, Nezih; Oksuzoglu, Berna; Ozyilkan, Ozgur; Artac, Mehmet; Ozdemir, Feyyaz; Kilickap, Sadettin
dc.date.accessioned2022-03-12T22:54:57Z
dc.date.available2022-03-12T22:54:57Z
dc.date.issued2021
dc.description.abstractObjective Cytokines have been the mainstay of treatment in metastatic renal cell cancer (mRCC) for decades before the introduction of tyrosine kinase inhibitors (TKIs), which dramatically changed the therapeutic landscape in these patients. This observational study was designed to evaluate use of TKIs in the treatment of cytokine-intolerant mRCC patients. Methods A total of 151 cytokine-intolerant mRCC patients who were treated with TKIs (sunitinib, pazopanib and sorafenib) were enrolled in this prospective, non-interventional, multi-center observational study at 16 oncology centers across Turkey. Mean (SD) age was 61.3 (11.1) years and 74.8% were males. Data on duration of TKI treatment was the primary outcome measure. Additionally, overall response rate (ORR), progression free survival (PFS), overall survival (OS) and safety data were recorded. Results Median duration of treatment was 8.2 months at a median follow up of 17.9 months. ORR and disease control rate were 12.5% and 70.8%, respectively. Median PFS and OS were 7.5 months (95%CI: 6.4-10.4) and 27.3 months (95%CI: 17.6-27.3) with no significant difference among three TKI agents in terms of treatment duration, ORR, PFS and OS. The most common adverse events excluding progression-which was the protocol requirement were diarrhea (13.6%), asthenia (13.6%) and hand-foot syndrome (12.6%). Dose modifications were required in 30.5% of the patients and 15% discontinued TKIs because of toxicity. Conclusions Our findings confirm the efficacy and safety profile of TKIs in the first-line treatment of mRCC patients intolerant to cytokine treatment. There was no significant difference among three TKI agents in terms of treatment duration, ORR, PFS and OS.
dc.identifier.doi10.1177/1078155220963535
dc.identifier.eissn1477-092X
dc.identifier.issn1078-1552
dc.identifier.pubmed33050804
dc.identifier.urihttps://hdl.handle.net/11424/236595
dc.identifier.wosWOS:000578499200001
dc.language.isoeng
dc.publisherSAGE PUBLICATIONS LTD
dc.relation.ispartofJOURNAL OF ONCOLOGY PHARMACY PRACTICE
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectMetastatic renal cell carcinoma
dc.subjecttyrosine kinase inhibitors
dc.subjectcytokine intolerance
dc.subjectprogression-free survival
dc.subjectoverall survival
dc.subjectsafety
dc.subjectINITIAL TARGETED THERAPY
dc.subjectPHASE-II TRIAL
dc.subjectINTERFERON-ALPHA
dc.subjectSYSTEMIC THERAPY
dc.subjectDOUBLE-BLIND
dc.subjectOPEN-LABEL
dc.subjectCARCINOMA
dc.subjectSORAFENIB
dc.subjectSUNITINIB
dc.subjectPAZOPANIB
dc.titleTyrosine kinase inhibitors in the treatment of metastatic renal cell cancer patients with early cytokine intolerance: TURCOS, a Turkish national, prospective observational study
dc.typearticle
dspace.entity.typePublication
local.avesis.id761eac20-9e0e-4edb-92dc-e3cf38ba25d0
local.import.packageSS17
local.indexed.atWOS
local.indexed.atSCOPUS
local.indexed.atPUBMED
local.journal.articlenumber1078155220963530
local.journal.numberofpages8
local.journal.quartileQ4
oaire.citation.endPage1630
oaire.citation.issue7
oaire.citation.startPage1623
oaire.citation.titleJOURNAL OF ONCOLOGY PHARMACY PRACTICE
oaire.citation.volume27
relation.isAuthorOfPublication059ce50a-8d16-4fc6-a86c-85c9baa19a5c
relation.isAuthorOfPublication.latestForDiscovery059ce50a-8d16-4fc6-a86c-85c9baa19a5c

Files

Collections

Research Outputs